Sanpeng Xu

1.5k citations
32 papers · 508 indexed · h-index 14
Topics
Cancer Genomics and Diagnostics (4 papers)Colorectal Cancer Treatments and Studies (3 papers)Lymphoma Diagnosis and Treatment (3 papers)

In The Last Decade

Sanpeng Xu

32 papers receiving 498 citations

Peers

Sanpeng Xu
Comparison fields: 5 of 73
  • Molecular Biology 193
  • Pulmonary and Respiratory Medicine 120
  • Cancer Research 112
  • Oncology 92
  • Pathology and Forensic Medicine 81
Replace Gila Idelman with:
Gila Idelman United States
Francesca Forini Italy
Elżbieta Korobowicz Poland
Peter Mirtschink Germany
Tatiana Novitskaya United States
Nataliya Skrypnyk United States
Stephanie Schwalm Germany
Padmini P. S. J. Khedoe Netherlands
Sanpeng Xu relative to Gila Idelman United States Gila Idelman's profile →
Citations per field
00.5×1.5×1.8×
Gila Idelman · 1×
Citations per year

Countries citing papers authored by Sanpeng Xu

Since Specialization
Citations

This map shows the geographic impact of Sanpeng Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sanpeng Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sanpeng Xu more than expected).

Fields of papers citing papers by Sanpeng Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sanpeng Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sanpeng Xu. The network helps show where Sanpeng Xu may publish in the future.

Co-authorship network of co-authors of Sanpeng Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Sanpeng Xu. A scholar is included among the top collaborators of Sanpeng Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sanpeng Xu. Sanpeng Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 3
3 26
4 6
5 2
6 14
7 12
8 32
9 34
10 7
11 9
12 2
13 24
14 11
15 4
16 23
17 32
18 44
19
Melatonin reduces acute lung injury in endotoxemic rats.
62
20 4

About Sanpeng Xu

Sanpeng Xu is a scholar working on Cancer Research, Pathology and Forensic Medicine and Dermatology, having authored 32 papers that have together received 508 indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (4 papers), Colorectal Cancer Treatments and Studies (3 papers) and Lymphoma Diagnosis and Treatment (3 papers). The work is most often cited by research in Cancer Research (112 citations), Endocrine and Autonomic Systems (37 citations) and Pathology and Forensic Medicine (81 citations). Sanpeng Xu has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Shiying Yuan, You Shang, Shanglong Yao, Guoping Wang, Zhouyang Wu, Yaqi Duan, Jie Wang, Peipei Guo, Dong Kuang and Shanglong Yao. Their work appears in journals such as Scientific Reports, Biochemical and Biophysical Research Communications and Oncotarget.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026